Claritev vs GoodRx
Claritev reported revenue of $965 million in fiscal 2025, 1.2 times GoodRx's $797 million in fiscal 2025. Claritev's revenue grew 3.7% in its latest year, and GoodRx's grew 0.6%. Claritev had an operating margin of 3.0%, against 11.0% at GoodRx. Free cash flow was −$12 million at Claritev and $164 million at GoodRx.
Side by side
| Claritev | GoodRx | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $965M | $797M |
| Revenue growth | 3.7% | 0.6% |
| Revenue growth a year, last 5 years | 0.6% | 7.7% |
| Gross margin | — | — |
| Operating margin | 3.0% | 11.0% |
| Net margin | −29.4% | 3.8% |
| Free cash flow | −$12M | $164M |
| Free cash flow margin | −1.3% | 20.6% |
| Return on capital | 0.5% | 5.8% |
| Net debt to EBITDA | 9.7x | 1.4x |
| Dividends and buybacks | $0M | $216M |
| Change in diluted share count | 1.8% | −9.0% |
| Last close | $19.03 | $3.02 |
| P/E at the last close | — | 75.5× |
| Insider trades, last 12 months | bought $1.9 million, sold $919,352 | sold $9.7 million |
| Piotroski F-score | 5 of 8 | 6 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ClaritevGoodRx
Operating margin
Percent of revenue
ClaritevGoodRx
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ClaritevGoodRx